BusinessAxsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionBy Nasdaq OMXApr 26, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsBy Nasdaq OMXMar 12, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXMar 17, 2016, 11:00 AM UTC
